tiprankstipranks
Trending News
More News >
Dermata Therapeutics announces last patient visit in Phase 3 acne trial
PremiumThe FlyDermata Therapeutics announces last patient visit in Phase 3 acne trial
2M ago
Dermata Therapeutics receives notice of acceptance for Australian patent
Premium
The Fly
Dermata Therapeutics receives notice of acceptance for Australian patent
2M ago
APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis
Premium
The Fly
APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis
2M ago
Dermata Therapeutics receives FDA approval for Xyngari proprietary name
PremiumThe FlyDermata Therapeutics receives FDA approval for Xyngari proprietary name
5M ago
Dermata Therapeutics completes enrollment in DMT310 Phase 3 STAR-1 trial
Premium
The Fly
Dermata Therapeutics completes enrollment in DMT310 Phase 3 STAR-1 trial
5M ago
Dermata Therapeutics files to sell 5.87M shares of common stock for holders
Premium
The Fly
Dermata Therapeutics files to sell 5.87M shares of common stock for holders
7M ago
Dermata achieves 50% enrollment in DMT310 Phase 3 STAR-1 clinical trial
PremiumThe FlyDermata achieves 50% enrollment in DMT310 Phase 3 STAR-1 clinical trial
10M ago
Dermata Therapeutics announces exercise of warrants for $2.66M
Premium
The Fly
Dermata Therapeutics announces exercise of warrants for $2.66M
12M ago
Dermata Therapeutics reports Q1 EPS (47c) vs. ($2.27) last year
Premium
The Fly
Dermata Therapeutics reports Q1 EPS (47c) vs. ($2.27) last year
12M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100